Search results
Results from the WOW.Com Content Network
For children with MRSA-infected bone or joints, treatment is individualized and long-term. Neonates can develop neonatal pustulosis as a result of topical infection with MRSA. [4] Clindamycin is not approved for the treatment of MRSA infection, but it is still used in children for soft-tissue infections. [4]
In October 2010, FDA approval was gained for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections, including MRSA. [15] MRSA can develop resistance to ceftaroline through the alteration of penicillin-binding proteins.
Because of the high level of resistance to penicillins and because of the potential for MRSA to develop resistance to vancomycin, the U.S. Centers for Disease Control and Prevention has published guidelines [121] for the appropriate use of vancomycin. In situations where the incidence of MRSA infections is known to be high, the attending ...
MRSA ST398 is resistant to many antimicrobial agents; therefore, treatment options for this strain are limited. [8] However, hospitalization and aggressive treatment to treat the symptoms of MRSA ST398 can be employed. And until more information about antimicrobial susceptibilities are known, the ST398 strain should be treated as MRSA is. [9]
Phages can be bioengineered to target multidrug-resistant bacterial infections, and their use involves the added benefit of preventing the elimination of beneficial bacteria in the human body. [31] Phages destroy bacterial cell walls and membrane through the use of lytic proteins which kill bacteria by making many holes from the inside out. [271]
By pre-emptively treating patients who have become colonized with an antimicrobial resistant organism, the likelihood of the patient going on to develop life-threatening healthcare-associated infections is reduced. Common sites of bacterial colonization include the nasal passage, groin, oral cavity and skin. [1]
Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics. [9] [10] Linezolid is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA).
Antibiotic resistance mediated by MDR plasmids severely limits the treatment options for the infections caused by Gram-negative bacteria, especially family Enterobacteriaceae. [5] The global spread of MDR plasmids has been enhanced by selective pressure from antimicrobial medications used in medical facilities and when raising animals for food. [6]